Stereotactic body radiation therapy: A good dance partner of oligometastatic non-small cell lung cancer to the sound of SINDAS study

Table 1 Prospective clinical trials in oligometastatic disease

Trial	Ref.	Design	Population	Number of lesions	Local treatment	PFS	OS
SABR-COMET	Palma et al[11]	Phase II, n = 99	≤ 5 locations; different tumour types (lung cancer; n = 18)	1-5	SABR	12 mo vs 6 mo, (P = 0.0012)	41 mo vs 28 mo, (P = 0.09)
	Iyengar et al[12]	Phase II, n = 29	Lung cancer patients treated with induction chemotherapy followed by standard maintenance treatment (+/-SBRT)	1-5	SABR	9.7 mo vs 3.5 mo, (P = 0.01)	Not reported
“Oligomez”	Gomez et al[13]	Phase II, n = 49	Lung cancer patients treated with induction chemotherapy followed by standard maintenance treatment (+/-SBRT)	1-3	XRT or Surgery	14.2 mo vs 4.4 mo, (P = 0.022)	41.2 mo vs 17 mo, (P = 0.017)
SINDAS	Wang e et al[14]	Phase III, n = 133	Front line treatment for EGFR + NSCLC patients with ≤ 5 metastases. EGFR-TKI vs SBRT + EGFR-TKI	1-5	SBRT	20.2 mo vs 12.5 mo, (P < 0.01)	25.5 mo vs 17.4 mo, (P < 0.01)

EGFR: Epidermal growth factor receptor; NSCLC: Non-small cell lung cancer; OS: Overall survival; PFS: Progression-free survival; SBRT: Stereotactic body radiation therapy; TKI: Tyrosine kinase inhibitor.